Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat and Pembrolizumab in Refractory GIST
NCT03291054Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Feb 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epacadostat in gastrointestinal stromal tumor (GIST), sponsored by Columbia University. Primary endpoint: Overall Response Rate at 24 weeks. Started Feb 2018; status: terminated.
02
Drugs
epacadostat
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03291054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291054.